Referenties
Barbui, C., Nose, M., Mazzi, M.A., Thornicroft, G., Schene, A., Becker, T., Bindman, J., Leese, M., Helm, H., Koeter, M., Weinmann, S., & Tansella, M. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21, 355-362.
Freudenreich, O., & Goff, D.C. (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica,
106, 323-330.
Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. British Journal of Psychiatry,
187, 243-247.
Suzuki, T., Uchida, H., Tanaka, K.F., Nomura, K., Takano, H., Tanabe, A., Watanabe, K., Yagi, G., & Kashima, H. (2004). Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. International Journal of Neuropsychopharmacology, 7, 133-142.
Waddington, J.L., Youssef, H.A., & Kinsella, A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 173, 325-329.